journal article·2021-11-10

Intravesical Mucoadhesive Hydrogel Induces Chemoresistant Bladder Cancer Ferroptosis through Delivering Iron Oxide Nanoparticles in a Three-Tier Strategy

Ao Qi, Chunyang Wang, Shaobin Ni, Yuyang Meng, Tengda Wang, Ziqi Yue, Kaiqi Yang, Yuqian Li, Zhe Cheng, Pengyu Guo, Cheng Zhang

ACS Applied Materials & Interfaces· Volume 13· Issue 44
Publisher page

Abstract

Bladder cancer (BCa) is the most costly solid tumor owing to its high recurrence. Relapsed cancer is known to acquire chemoresistant features after standard intravesical chemotherapy. This cancer state is vulnerable to ferroptosis, which occurs when lipid peroxides generated by iron metabolism accumulate to lethal levels. Increasing the labile iron pool (LIP) by iron oxide nanoparticles (IONPs) promises to inhibit chemoresistant BCa (CRBCa), but systemically administered IONPs do not sufficiently accumulate at the tumor site. Therefore, their efficacy is weakened. Here, we present a three-tier delivery strategy through a mucoadhesive hydrogel platform conveying hyaluronic acid-coated IONPs (IONP-HA). When instilled, the hydrogel platform first adhered to the interface of the tumor surface, sustainably releasing IONP-HA. Subsequently, the tumor stiffness and interstitial fluid pressure were reduced by photothermal therapy, promoting IONP-HA diffusion into the deep cancer tissue. As CRBCa expressed high levels of CD44, the last delivery tier was achieved through antibody-mediated endocytosis to increase the LIP, ultimately inducing ferroptosis. This three-tiered strategy delivered the IONPs stepwise from anatomical to cellular levels and increased the iron content by up to 50-fold from that of systematic administration, which presents a potential regimen for CRBCa.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bladder and Urothelial Cancer Treatments · Ferroptosis and cancer prognosis · Inflammatory Biomarkers in Disease Prognosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Urology Surgery Department, The First Affiliated Hospital of Harbin Medical University, Yiyuan Street #37, Nangang District, Harbin 150001, P. R. China

Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Youzheng Street #23, Nangang District, Harbin 150001, P. R. China

Department of Forensic Medicine, Harbin Medical University, Baojian Road #157, Nangang District, Harbin 150001, P. R. China

Urology Surgery Department, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Shangchengdadao Street #N1, Yiwu 322000, P. R. China

Funding

China Postdoctoral Science Foundation · Undergraduate innovation and Entrepreneurship

References (33)

Show source-provided references
1. 10.1016/j.eururo.2019.08.01610.1016/j.eururo.2019.08.016 ↗
2. 10.1016/j.eururo.2020.12.03310.1016/j.eururo.2020.12.033 ↗
3. 10.1111/bju.1533610.1111/bju.15336 ↗
4. 10.3322/caac.2135010.3322/caac.21350 ↗
5. 10.1038/s41419-020-2298-210.1038/s41419-020-2298-2 ↗
6. 10.1016/j.ccell.2019.04.00210.1016/j.ccell.2019.04.002 ↗
7. 10.1016/j.tcb.2017.11.00710.1016/j.tcb.2017.11.007 ↗
8. 10.1038/s41589-019-0408-110.1038/s41589-019-0408-1 ↗
9. 10.1002/adma.20190419710.1002/adma.201904197 ↗
10. 10.1016/j.addr.2019.01.00510.1016/j.addr.2019.01.005 ↗
11. 10.1021/acs.accounts.6b0062910.1021/acs.accounts.6b00629 ↗
12. 10.1002/anie.20151003110.1002/anie.201510031 ↗
13. 10.1002/adma.20170400710.1002/adma.201704007 ↗
14. 10.1038/nmat471810.1038/nmat4718 ↗
15. 10.1111/iju.1341010.1111/iju.13410 ↗
16. 10.1308/003588407X20558510.1308/003588407X205585 ↗
17. 10.1016/j.jconrel.2010.08.03110.1016/j.jconrel.2010.08.031 ↗
18. 10.1016/j.tibtech.2019.12.01210.1016/j.tibtech.2019.12.012 ↗
19. 10.1038/nrc145610.1038/nrc1456 ↗
20. 10.1080/14728222.2019.170297410.1080/14728222.2019.1702974 ↗
21. 10.1016/j.tibtech.2018.10.00710.1016/j.tibtech.2018.10.007 ↗
22. 10.1038/nrd.2015.1310.1038/nrd.2015.13 ↗
23. 10.1186/s12894-020-00610-910.1186/s12894-020-00610-9 ↗
24. 10.1021/acsami.0c1517610.1021/acsami.0c15176 ↗
25. 10.1016/j.jconrel.2018.06.03610.1016/j.jconrel.2018.06.036 ↗
26. 10.1158/1535-7163.MCT-18-021210.1158/1535-7163.MCT-18-0212 ↗
27. 10.1038/nature2300710.1038/nature23007 ↗
28. 10.1016/j.freeradbiomed.2018.09.01410.1016/j.freeradbiomed.2018.09.014 ↗
29. 10.1021/acs.langmuir.9b0230010.1021/acs.langmuir.9b02300 ↗
30. 10.1016/j.jconrel.2020.01.00810.1016/j.jconrel.2020.01.008 ↗
31. 10.1038/s41585-019-0220-410.1038/s41585-019-0220-4 ↗
32. 10.1016/j.bioactmat.2020.11.02010.1016/j.bioactmat.2020.11.020 ↗
33. 10.1016/j.carbpol.2015.06.01010.1016/j.carbpol.2015.06.010 ↗